HSBC Maintains Reduce on Biogen, Raises Price Target to $150

Benzinga Newsdesk www.benzinga.com Positive 61.7%

Neg 0% Neu 0% Pos 61.7%

HSBC analyst Rajesh Kumar maintains Biogen (NASDAQ:BIIB) with a Reduce and raises the price target from $143 to $150.

Comments

No comments yet. Be the first!